1917
It is founded
Istituto Gentili
1917-97
Marketing
of products under the
Istituto Gentili brand
2009
The
Mediolanum
pharmaceutical group
takes over the Istituto Gentili
from Merck Sharp & Dohme
Italia group
2017
AcquisitionTherabel
by the
Mediolanum Pharmaceutical
group
2017
With the deal with
Novartis Farma S.p.A
the new reality of Istituto Gentili
is born,
entirely focused on
oncology
2018
The
acquisition of
Teva's Italia Srl OncoCare products
further strengthens
the Portfolio of
Istituto Gentili's products
2020
Acquisition
of 3 products
that allowed to expand the
company's response
to the fight
against breast cancer
2021
Acquisition of one product dedicated to supportive
therapies for cancer patients.
2021
The deal with Norgine Italia has consolidated the company's commitment to support the cancer patient at 360°
2022
The consolidated deal with Novartis Farma S.p.A. strengthens the company's commitment in oncology (kidney cancer and soft tissue sarcomas)
2023
L'acquisizione del prodotto RYDAPT rafforza ulteriormente l'impegno di Istituto Gentili in oncoematologia e malattie rare (leucemia mieloide acuta e mastocitosi sistemica)
2024
With the treatment of acromegaly and neuroendocrine tumors (NETs), Istituto Gentili intensifies its commitment to the world of rare diseases and oncology, thanks to its new deal with Novartis S.p.A.
2024
Istituto Gentili strengthens its commitment to fighting pain by providing increasingly effective solutions to address the different facets of pain.
